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I-Chow Hsu, MD 
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Abstract 
Purpose: Three-dimensional (3D) printing technology allows physicians to rapidly create customized devices 
for patients. We report our initial clinical experience using this technology to create custom applicators for vaginal 
brachytherapy. 
Material and methods: Three brachytherapy patients with unique clinical needs were identified as likely to benefit 
from a customized vaginal applicator. Patient 1 underwent intracavitary vaginal cuff brachytherapy after hysterec-
tomy and chemotherapy for stage IA papillary serous endometrial cancer using a custom printed 2.75 cm diameter 
segmented vaginal cylinder with a central channel. Patient 2 underwent interstitial brachytherapy for a vaginal cuff 
recurrence of endometrial cancer after prior hysterectomy, whole pelvis radiotherapy, and brachytherapy boost. We 
printed a 2 cm diameter vaginal cylinder with one central and six peripheral catheter channels to fit a narrow vaginal 
canal. Patient 3 underwent interstitial brachytherapy boost for stage IIIA vulvar cancer with vaginal extension. For 
more secure applicator fit within a wide vaginal canal, we printed a 3.5 cm diameter solid cylinder with one central 
tandem channel and ten peripheral catheter channels. The applicators were printed in a biocompatible, sterilizable 
thermoplastic. 
Results: Patient 1 received 31.5 Gy to the surface in three fractions over two weeks. Patient 2 received 36 Gy to the 
CTV in six fractions over two implants one week apart, with interstitial hyperthermia once per implant. Patient 3 re-
ceived 18 Gy in three fractions over one implant after 45 Gy external beam radiotherapy. Brachytherapy was tolerated 
well with no grade 3 or higher toxicity and no local recurrences. 
Conclusions: We established a workflow to rapidly manufacture and implement customized vaginal applicators 
that can be sterilized and are made of biocompatible material, resulting in high-quality brachytherapy for patients 
whose anatomy is not ideally suited for standard, commercially available applicators. 
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Purpose 
In an effort to improve applicator fit and resulting im-
plant geometry, we used three-dimensional (3D) printing 
technology as a way to rapidly manufacture customized 
brachytherapy applicators for women undergoing vag-
inal brachytherapy. Poor applicator fit during vaginal 
intracavitary brachytherapy can lead to air gaps and 
under-dosing of the target volume [1,2]. For interstitial 
implants, poor applicator fit may lead to poor implant 
geometry and increased inter-fraction variability when 
multiple fractions are delivered over a single implant [3]. 
While commercial applicators are available in a variety 
of sizes, we desired further flexibility in applicator shape 
and structure to improve fit within a cavity or allow op-
timal needle positioning for interstitial technique. While 
other centers have documented interest in personalized 
vaginal applicators [4,5] and one group has reported us-
ing stereolithography to create vaginal applicators [6], we 
know of no prior experience using rapid prototyping with 
3D in conjunction with an interstitial technique. 
Medical applications of 3D printing in development 
include medical modeling for maxillofacial surgical man-
agement [7,8] bone reconstructions [9,10], and oral sur-
geries [11]. The precision of 3D printers has been closely 
evaluated for medical applications with several studies 
confirming high levels of precision [12,13,14]. Manufac-
turers have supported medical interests in 3D printing by 
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introducing printing materials that pass the International 
Standard ISO-10993 as well as the United States Pharma-
copeia (USP) standards for biocompatibility. 
In this article, we present the clinical implementation 
of rapid prototype 3D printed custom, biocompatible, 
sterilizable vaginal applicators at our institution, using ex-
amples from three patients with unique clinical scenarios. 
Material and methods 
Applicator design and production 
Computer aided design (CAD) software (Autodesk, 
Inc., San Francisco, CA, USA) was used to create a design 
file for a desired applicator shape, which is directly read 
by a 3D printer for production in thermoplastic. In our 
work-flow, the applicator shape is based on dimensions 
estimated from physical examination and imaging. Surface 
channels for interstitial needles are placed to allow optimal 
spacing between needles for high-dose-rate brachytherapy, 
approximately 1 cm apart. A central channel for a tandem, 
rod, or catheter can be incorporated as needed. We deter-
mined which plastics could be printed and sterilized, and 
we selected PC-ISO, a thermoplastic that is both USP Class 
VI approved and ISO-10993-1 rated (Stratasys Ltd., Eden 
Prairie, MN, USA). The material is also sterilizable and has 
high flexural and tensile strength properties that have made 
it a common choice for many medical applications, includ-
ing ankle-foot orthoses, lumbar cages, and bone screw link-
ing devices [10,15,16,17,18]. Documentation was obtained 
of an independent study describing the effectiveness of the 
STERRAD sterilization system (Ethicon, Inc., Sommerville, 
NJ, USA) for use with PC-ISO [19]. 
Multiple quality assurance and physical evaluations 
were performed on prototypes to ensure suitability for 
clinical use, which were reported in a separate technical 
paper [20]. 
Patient 1 
Patient 1 was a 56 year-old woman with stage IA se-
rous endometrial cancer who was referred for vaginal 
cuff brachytherapy following chemotherapy. Based on 
physical examination, the optimal applicator size was 
determined to be a 2.75 cm diameter vaginal cylinder. 
Because vaginal cylinder applicators at our institution 
are available only in 2.5, 3, or 3.5 cm diameter sizes, 
we decided to produce a custom-sized applicator using 
three-dimensional printing technology to better fit this 
patient’s anatomy. This simple case also served as a proof 
of concept for the initial clinical implementation of a 3D 
printed custom vaginal applicator in our clinic. We used 
CAD software (Autodesk, Inc., San Francisco, CA, USA) 
to design a 2.75 cm diameter segmented cylinder with 
a single central channel. The cylinder was printed on 
a Fortus 400mc (Stratasys Ltd., Eden Prairie, MN, USA) 
three-dimensional printer, using PC-ISO biocompatible 
thermoplastic (Figure 1). The thermoplastic cylinder was 
sterilized using a STERRAD (Ethicon, Inc., Sommerville, 
NJ, USA) sterilization system. 
At the time of treatment, two gold seed fiducial mark-
ers were inserted into the vaginal cuff prior to the first 
insertion. The sterilized cylinder was placed in the vagi-
na, secured with a metal applicator clamp and baseplate, 
and the position was verified on scout film. Computed 
tomography images of the treatment area were obtained, 
and the applicator and organs at risk were contoured on 
Elekta Nucletron Oncentra Planning System (Verson 4.3; 
Elekta Instrument AB, Stockholm, Sweden). Three-di-
mensional inverse planning using inverse planning sim-
ulated annealing algorithm (IPSA) was used to develop 
a treatment plan to deliver 31.5 Gy over three fractions of 
10.5 Gy per fraction, prescribed to the surface of the va-
gina. The applicator surface was used as a proxy for vag-
inal surface for the purposes of treatment planning. The 
IPSA class solution was designed with the goal of achiev-
ing 10.5 Gy to the surface of vagina. The length of vagina 
treated was based on physician’s contour, which included 
the upper two-thirds of the vaginal canal. Coverage was 
verified by visual confirmation of the confluence of the 
10.5 Gy isodose surface with the applicator surface. 3D 
volumetric doses were calculated for the bladder, rectum, 
bowel, and the target volume. The treatment was deliv-
ered using Elekta Nucletron microSelectron V3 remote 
afterloader (Elekta Instrument AB, Stockholm, Sweden). 
Patient 2 
Patient 2 was a 67-year-old woman with vaginal cuff 
recurrence of stage IA grade 1 endometrioid endometrial 
cancer who had initially undergone total abdominal hys-
terectomy and bilateral salpingo-oophorectomy showing 
inner half myometrial invasion, grade 1 disease, and no 
lymphovascular invasion, who subsequently developed 
a vaginal cuff recurrence one year later and was treated 
with whole pelvis external beam radiotherapy to a dose of 
45 Gy, followed by vaginal cuff brachytherapy to a dose 
of 15 Gy over three fractions to the surface. Two years lat-
er, she developed a second vaginal cuff recurrence as well 
as distant metastatic disease and was referred for pallia-
Fig. 1. Picture of the custom printed segmented cylinder 
sections with 2.75 cm diameter. The segments are stacked 
onto a plastic rod with a central channel for treatment as 
shown 
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tive brachytherapy to a 2.4 × 2.7 cm necrotic vaginal cuff 
mass causing progressive vaginal bleeding. Due to her 
prior treatment, the vaginal canal was very stenotic, and 
our narrowest commercial applicator could not be com-
fortably inserted. We therefore decided to print a vaginal 
cylinder applicator of 2 cm diameter, with a central cathe-
ter channel as well as six evenly spaced longitudinal sur-
face grooves for interstitial brachytherapy to the vaginal 
cuff mass (Figure 2). Distance between surface grooves 
was 1 cm. We used the same printing process and equip-
ment as described for patient 1. 
At the time of treatment, two marker seeds were 
placed at the vaginal cuff. The patient underwent free-
hand trans-rectal ultrasound (TRUS)-guided interstitial 
brachytherapy. During this procedure, trans-rectal ultra-
sound was used to guide free-hand placement of flexible 
30 cm interstitial catheters into the para-vaginal and vag-
inal cuff tissue. Additional catheters were placed along 
the surface and central channels of the vaginal cylinder to 
allow further dose modulation. The cylinder was secured 
to the vagina using sutures, and the catheters were se-
cured to the cylinder using dental putty. For this patient, 
the final implant consisted of nine interstitial catheters, 
with six surface catheters around the cylinder, one central 
catheter, and two paravaginal catheters (Figure 3). She re-
ceived 36 Gy over two implants, with 6 Gy per fraction 
and three fractions per implant prescribed to the CTV. 
CT-simulation and inverse planning were used, incorpo-
rating pre-operative MRI scan to guide tumor delineation. 
The CTV, bladder, rectum, and bowel were contoured. 
IPSA was used for planning. The IPSA class solution was 
designed to maximize the volume of the CTV receiving 
at least the prescription dose, minimize hotspots in the 
CTV (V150%), and keep the V75% of the bladder, rectum, 
and bowel below 1 cm3. 
This patient also received two interstitial hyperther-
mia treatments, once during each implant. Hyperthermia 
was delivered using the BSD 500 System (BSD Medical 
Corporation, Salt Lake City, UT, USA), with MA-251 in-
terstitial microwave antenna and temperature monitoring 
sensors inserted within selected implant catheters. Target 
temperatures of 39.5-45 C for 60 min were prescribed, to 
be delivered immediately following treatment of either 
the first or second brachytherapy fraction. Hyperthermia 
treatment parameters included four or five microwave 
antennae with 4-6 W applied power per antenna, and 
four temperature sensors within adjacent catheters. 
Patient 3 
Patient 3 was a 37 year-old female with stage IIIA 
(cT2N2bM0) squamous cell carcinoma of the vulva, with 
a 6 cm fungating vulvar mass extending from the low-
er vagina to the anal verge, who underwent definitive 
chemoradiation. For treatment of the primary tumor, she 
received 45 Gy external beam radiation to the vulva with 
weekly cisplatin, followed by an interstitial brachyther-
apy boost to deliver an additional 18 Gy over three frac-
tions in a single implant to the residual gross disease. She 
had a wide vaginal canal, and we printed a 3.5 cm di-
ameter cylinder with a central channel for a tandem and 
ten surface grooves spaced 1.1 cm apart to accommodate 
peripheral surface catheters. 
During the interstitial procedure, she underwent 
placement of gold seed markers to delineate tumor ex-
tent. She underwent subcutaneous insertion of four 
brachytherapy catheters, two through the left labia ma-
jora and two through the right labia majora. Nine addi-
tional flexible catheters were inserted transperineally into 
the bilateral paravaginal tissues (five on the left and four 
on the right) under palpation and ultrasound guidance. 
A uterine tandem and the custom printed 3.5 cm diame-
ter vaginal cylinder were then placed, and ten additional 
catheters were inserted along the surface channels of the 
cylinder. The cylinder was tied in place with vaginal su-
tures, and the entire implant was secured together using 
dental putty around the cylinder and catheters. We fol-
lowed the same applicator printing and treatment plan-
Fig. 2. Picture of the 2 cm diameter custom printed vaginal 
cylinder with six external catheter channels and one cen-
tral catheter channel for use in interstitial brachytherapy 
and hyperthermia in a patient with a very narrow vaginal 
vault after prior surgery and radiotherapy
Fig. 3. Picture of the 3.5 cm diameter custom printed 
vaginal cylinder with ten external catheter channels and 
one central channel for a tandem for use in interstitial 
brachytherapy in a patient with a wide vaginal vault
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ning processes as described for patient 2, with additional 
planning parameters used to keep skin dose below 100% 
of the prescription dose. 
Results 
Patient 1 
The patient tolerated the 2.75 cm cylinder without 
discomfort, and there were no air-gaps seen at the time 
of CT-simulation. The plan is depicted in Figure 4. Dose 
volume histogram (DVH) parameters for each fraction 
were as follows: bladder V75% = 0.01 cc, V85% = 0 cc, D2cc 
= 6.53 Gy; rectum V75% = 0.95 cc, V85% = 0.06 cc, D2cc = 
7.31 Gy; bowel V75% = 0 cc, V85% = 0 cc, D2cc = 4.68 Gy; 
CTV V100% = 90%. The patient experienced no acute treat-
ment effects other than mild fatigue for two weeks. After 
eighteen months of follow-up, she has had no evidence 
of disease on exam. She developed small adhesions at the 
vaginal apex six months after treatment, for which regu-
lar vaginal dilator use was encouraged. She had no other 
acute or late side effects of treatment. 
Patient 2 
The brachytherapy plan for implant 1 is depicted in 
Figure 5. Dose volume histogram parameters for each 
fraction were as follows: bladder V75% = 0.24 cc, V85% = 
0.01 cc, D2cc = 3.80 Gy; rectum V75% = 0.24 cc, V85% = 0 cc, 
D2cc = 3.69 Gy; bowel V75% = 0.4 cc, V85% 0 cc, D2cc = 3.24 Gy; 
CTV V100% = 91%. 
First hyperthermia treatment was delivered as pre-
scribed using four interstitial applicators, with 4-6 W 
power applied to each antenna, generating target tem-
peratures between 40-43.9°C for 60 min duration, and 
thermal dose between 1-49 EM43°C (equivalent minutes 
at 43°C). Second hyperthermia treatment utilized five 
interstitial applicators, with 4.5-5.5 W applied power, 
with temperatures of 39.4-44.8°C, and thermal dose 2-28 
EM43°C achieved. 
The patient had complete cessation of bleeding at 
her one-month follow-up appointment. She experienced 
fatigue and clear vaginal discharge for one month after 
treatment. MRI of the pelvis three months after treatment 
showed reduction in size of the vaginal mass, now mea-
suring 1.9 × 1.4 cm. She died of progressive metastatic 
disease nine months after treatment without recurrence 
of vaginal bleeding. 
Patient 3 
The brachytherapy implant and treatment plan are 
depicted in Figure 6. Dose volume histogram parameters 
Fig. 4. Axial, sagittal, and coronal views of the brachytherapy treatment plan for patient 1. Bold line indicates the gross target 
volume and is drawn at the surface of the cylinder, which is depicted with hyperintense central rod, around which are situated 
the segments of the cylinder. The 50%, 100%, and 150% isodose lines, as well as organs at risk including the bowel, bladder, 
and rectum, are depicted 
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Fig. 5. Axial, sagittal, and coronal views of the brachytherapy treatment plan for patient 2. Bold line indicates the gross target 
volume. The 50%, 100%, and 150% isodose lines, as well as organs at risk including the bowel, bladder, and rectum, are depicted 
Fig. 6. Axial, sagittal, and coronal views of the brachytherapy treatment plan for patient 3. Bold line indicates the gross target 
volume. The 50%, 100%, and 150% isodose lines, as well as organs at risk including the bowel, bladder, and rectum, are depicted 
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for each fraction were as follows: bladder V75% = 0 cc, 
V85% = 0 cc, D2cc = 1.32 Gy; rectum V75% = 0.04 cc, V85% = 0 cc, 
D2cc = 3.02 Gy; skin D0.1cc = 5.24 Gy, D2cc = 3.08 Gy, D1cc = 
3.63 cGy; CTV V100% = 95.4%. 
She is currently without evidence of disease after 
six months of follow-up. She developed acute grade 2 
dysuria and pelvic and perineal pain requiring pyridium 
and narcotics for three weeks. 
Discussion 
We established the clinical feasibility of using 3D 
printed custom applicators for vaginal brachytherapy 
and, for two patients, in conjunction with interstitial 
brachytherapy. We have found these applicators useful 
for women whose anatomy falls outside the range of 
commercial applicators. In particular, patient 2 would 
not have been able to tolerate even the smallest commer-
cial applicator at our institution (2.5 cm diameter), and 
the printed applicator (2.0 cm diameter) made her im-
plant feasible. Additionally, the wider diameter cylinder 
used for patient 3 allowed for more secure fit in a wide 
vaginal canal, while also permitting optimal placement 
of surface grooves for interstitial technique. In order to 
clinically implement these applicators while ensuring 
patient safety, multiple challenges in the design, man-
ufacturing, and clinical application needed to be ad-
dressed. 
With respect to applicator design, estimation of fit was 
based on physical exam. In the future, inverse applica-
tor design based on imaging may be employed. Imaging 
techniques would need to incorporate either a real-time 
or post-processed expansion of the relaxed vaginal cav-
ity. A volumetric contour could then be converted into 
a computer aided design file for 3D printing. One group 
recently reported on their process using CT scans with 
contrast-soaked vaginal gauze in place to delineate appli-
cator shape for use with stereolithography [6]. 
The manufacturing process posed several challenges, 
including the need to perform proper QA of the custom 
applicators. When designing custom built applicators, 
the brachytherapy team takes on some of the roles tra-
ditionally filled by the vendor/manufacturer, therefore 
a fundamental understanding of the properties of the 
applicator is required. A suitable material needed to be 
selected and subjected to multiple quality assurance tests 
to document its feasibility for clinical use. Namely, the 
thermoplastic we selected needed to be biocompatible, 
sterilizable, CT-compatible, and have dose-attenuation 
properties similar to water in order to be compatible with 
our brachytherapy planning system. 
We selected PC-ISO because at the time of this work 
it was one of a few materials with International Stan-
dard ISO-10993 Class VI Certification for biocompati-
bility, meaning it is FDA approved for temporary skin 
contact [10,15], and it is sterilizable [19]. However, the 
current market of printing materials is expanding rap-
idly because of the wide range of medical applications 
for 3D printing and vendors are now providing a range 
of materials that are certified as both biocompatible 
and sterilizable. However, it is important for the clinic 
to verify that the sterilization systems available in your 
hospital has been validated by the vendor as a suitable 
system. 
Computed tomography compatibility and dose-at-
tenuation properties of the material are straightforward 
to determine; and once measured are valid for all uses 
of the material. The main issues to be careful with are 
the resolution of the printer used for manufacturing and 
the homogeneity of the final product. Though planning 
technology to handle tissue inhomogeneities are com-
mon in external beam planning, both Varian and Elek-
ta brachytherapy treatment planning systems use TG-43 
formalism, and assume all applicators and tissues are wa-
ter. A straightforward method for determining the water 
equivalence of the chosen 3D printing material is to use 
gafchromic film embedded in a 3D printed sample of the 
material. 
For readers interested in more detail, each of the QA 
elements discussed above are covered in our recently 
published technical paper [20]. 
During the planning process for patient 1, we noticed 
that the density of PC-ISO is virtually tissue-equivalent 
on CT, making applicator delineation somewhat diffi-
cult during CT-based planning. This can be addressed 
by placing a small amount of contrast between the cyl-
inder and condom cover prior to insertion at the time 
of simulation. Applicator delineation for patients 2 and 
3 was facilitated by the surface grooves for peripheral 
catheters. 
All three cases in this study were performed using CT 
for image-based planning. Magnetic resonance imaging, 
however, is beginning to see more use in gynecological 
brachytherapy because of its enhanced soft tissue con-
trast MRI, increased availability, and publication of mul-
tiple sets of guidelines regarding its use in gynecologic 
brachytherapy over the past decade. It should be noted 
that while CT compatibility and photon attenuation are 
intimately related, the same is not true for MRI. Materials 
should be independently verified to not have any ferro-
magnetic properties. In addition, if the custom applicator 
design is to have internal channels for the brachytherapy 
catheters, it is important that the MR imaging can resolve 
them for digitization. If this is not the case, a method for 
introducing contrast into the brachytherapy channels 
should be developed. 
Conclusions 
We used 3D printing technology to produce biocom-
patible, sterilizable, custom applicators for patients un-
dergoing gynecologic brachytherapy for whom standard 
applicators would have resulted in suboptimal implants. 
3D printing enabled rapid production of applicators with 
excellent fit and optimized interstitial needle placement 
to enable target coverage, normal tissue sparing, and im-
plant stability. In the future, this clinical workflow could 
easily be adapted to allow more complicated surface 
contours and irregular shaped applicators inversely de-
signed from imaging. 
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